General Information of DTT (ID: TT846HF)

DTT Name Voltage-gated potassium channel Kv7.1 (KCNQ1) DTT Info
Gene Name KCNQ1

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
1 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indapamide DMGN1PW Edema MG29 Approved [1]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-768673 DMZ402C N. A. N. A. Terminated [2]
------------------------------------------------------------------------------------
13 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
(3R,4S)-293B DM47BEG Discovery agent N.A. Investigative [3]
3S,4R-293B DMVGDSM Discovery agent N.A. Investigative [3]
HMR-1556 DMXMTA9 Discovery agent N.A. Investigative [4]
IKs124 DMLY5IF Discovery agent N.A. Investigative [5]
L-735,821 DMY60MG Discovery agent N.A. Investigative [6]
ML277 DMQ98RS Discovery agent N.A. Investigative [7]
N-(2-Diethylamino-ethyl)-4-hexyloxy-benzamide DMZ4A2X Discovery agent N.A. Investigative [8]
N-(3,3-Dimethyl-butyl)-4-hexyloxy-benzamide DM2Y5AP Discovery agent N.A. Investigative [8]
N-(3,3-Dimethyl-butyl)-4-indol-1-yl-benzamide DMEUXOQ Discovery agent N.A. Investigative [8]
N-(3,3-Dimethyl-cyclopentyl)-4-hexyloxy-benzamide DM6EJQ4 Discovery agent N.A. Investigative [8]
R-L3 DMGEDQJ Discovery agent N.A. Investigative [9]
XE991 DMLH1PK Discovery agent N.A. Investigative [10]
zinc pyrithione DMF0CRA Discovery agent N.A. Investigative [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Investigative Drug(s)
Molecule Interaction Atlas

References

1 Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84.
2 Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(... J Med Chem. 1997 Nov 21;40(24):3865-8.
3 A kinetic study on the stereospecific inhibition of KCNQ1 and I(Ks) by the chromanol 293B. Br J Pharmacol. 2001 Dec;134(8):1647-54.
4 Selective optimization of side activities: another way for drug discovery. J Med Chem. 2004 Mar 11;47(6):1303-14.
5 Heteromeric KCNE2/KCNQ1 potassium channels in the luminal membrane of gastric parietal cells. J Physiol. 2004 Dec 1;561(Pt 2):547-57.
6 Molecular determinants of KCNQ1 channel block by a benzodiazepine. Mol Pharmacol. 2003 Jul;64(1):70-7.
7 Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5936-41.
8 Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers. J Med Chem. 2001 Nov 8;44(23):3764-7.
9 A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents. Mol Pharmacol. 1998 Jul;54(1):220-30.
10 Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. Mol Pharmacol. 2000 Jun;57(6):1218-23.
11 Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96.